Stockreport

Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome

Neurogene Inc.  (NGNE) 
PDF Designation based on preliminary clinical evidence from ongoing NGN-401 clinical trial that shows potential to address unmet medical needs in Rett syndromeRMAT designati [Read more]